Abstract | BACKGROUND AND OBJECTIVE: MATERIALS AND METHODS: Four groups of rats were used: lean Zucker rats, untreated obese Zucker rats, AM 251-treated obese Zucker rats and a pair-fed obese Zucker rat experimental group which received the same amount of food as that consumed by the animals treated with AM251. Food intake, body weight gain, energy expenditure, plasma biochemical parameters, leptin, insulin and hepatic status markers were analysed. RESULTS: Daily injection of AM 251 in obese Zucker rats produced a marked and sustained decrease in daily food intake and body weight and a considerable increase in energy expenditure in comparison with untreated obese Zucker rats. AM 251 administration to obese rats significantly reduced plasma levels of glucose, leptin, AST, ALT, Gamma GT, total bilirubin and LDL cholesterol whereas HDL cholesterol plasma levels increased. The results also showed a decrease in liver/ weight body ratio and total fat content in the liver. The main effects of AM251 (3 mg/kg) found in this study were not observed in pair-fed obese animals, highlighting the additional beneficial effects of treatment with AM 251. The results obtained in obese rats can be interpreted as a decrease in leptin and insulin resistance, thereby improving glucose and lipid metabolism, alleviating the steatosis present in the metabolic syndrome and thus favourably modifying plasma levels of hepatic biomarkers. CONCLUSION:
|
Authors | Ikram Merroun, Cristina Sánchez-González, Rosario Martínez, Carlos López-Chaves, Jesús M Porres, Pilar Aranda, Juan Llopis, Milagros Galisteo, Antonio Zarzuelo, Mohammed Errami, María López-Jurado |
Journal | Metabolism: clinical and experimental
(Metabolism)
Vol. 62
Issue 11
Pg. 1641-50
(Nov 2013)
ISSN: 1532-8600 [Electronic] United States |
PMID | 23932644
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013. |
Chemical References |
- Biomarkers
- Cannabinoid Receptor Antagonists
- Insulin
- Leptin
- Piperidines
- Pyrazoles
- Receptor, Cannabinoid, CB1
- AM 251
|
Topics |
- Animals
- Biomarkers
(blood)
- Cannabinoid Receptor Antagonists
(pharmacology)
- Eating
(drug effects)
- Energy Metabolism
(drug effects)
- Fatty Liver
(metabolism, prevention & control)
- Insulin
(blood)
- Insulin Resistance
- Leptin
(blood)
- Lipid Metabolism
- Liver
(drug effects, metabolism)
- Male
- Metabolic Syndrome
(blood, drug therapy, metabolism, physiopathology)
- Obesity
(blood, drug therapy, metabolism, physiopathology)
- Piperidines
(pharmacology)
- Pyrazoles
(pharmacology)
- Rats
- Rats, Zucker
- Receptor, Cannabinoid, CB1
(antagonists & inhibitors, metabolism)
- Weight Gain
(drug effects)
|